Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Portfolio Pulse from Vandana Singh
Moderna's investigational mpox vaccine, mRNA-1769, shows greater effectiveness than the current Jynneos vaccine in animal studies. The vaccine is in Phase 1/2 trials, with results expected in 2025. BioNTech is also developing a similar vaccine. Moderna's stock is down 1.39%.
September 06, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's mRNA-1769 vaccine shows promising results in animal studies, outperforming the Jynneos vaccine. The ongoing Phase 1/2 trial results are expected in 2025. Despite this, Moderna's stock is down 1.39%.
The news highlights the potential of Moderna's new vaccine, which could lead to future revenue if successful. However, the stock is currently down, possibly due to broader market conditions or other factors not mentioned in the article.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
BioNTech is developing an mRNA mpox vaccine, BNT166a, which is in Phase 1/2 trials. Results are expected in May 2025, similar to Moderna's timeline.
BioNTech's development of a similar vaccine positions it as a competitor to Moderna. The outcome of their trials will determine future market dynamics.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Bavarian Nordic's Jynneos vaccine is less effective than Moderna's mRNA-1769 in animal studies. This could impact its market position if Moderna's vaccine proves successful in human trials.
The study suggests Moderna's vaccine is more effective, which could reduce demand for Jynneos if Moderna's vaccine is approved and commercialized.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70